REFERENCES
tumor, necrotic, Tumors, primary lung adenocarcinoma, adenocarcinoma, Lung Cancer
ADHESION, TUMOR, LUNG, NECROTIC, TUMORS, ADHESION, ADENOCARCINOMA, LUNG CANCER
SGM-101–Guided Lung Nodule Resection in a Control PatientA, Computed tomography images of the tumor (yellow arrowheads indicate tumor). B, Nodule 1. C, Nodule 2. NIR indicates near infrared.Association of SGM-101 Fluorescence With Carcinoembryonic Antigen–Related Cell Adhesion Molecule Type 5 (CEACAM5) Presence by Immunohistochemical AnalysisScale bars = 100 μm.Localization of SGM-101 to Carcinoembryonic Antigen–Related Cell Adhesion Molecule Type 5 (CEACAM5) TumorsPatient 8 with invasive adenocarcinoma demonstrated a tumor with a large necrotic core (>80%) but had high CEACAM5 staining correlating with the thyroid transcription factor 1 (TTF-1) score (scale bar = 100 μm). Tumors were able to localize in vivo, ex vivo, and on a near-infrared scanner. AU indicates absorbance units; CK5/6, cytokeratin 5/6.Fluorescence Microscopy Assessment of Primary Lung Nodules Analyzed in the StudyThe benign lesion (A) demonstrates no uptake of SGM-101 fluorescence, which corresponded with a lack of carcinoembryonic antigen, p63, and thyroid transcription factor 1 (TTF-1) staining (scale bar = 100 μm). Conversely, malignant lesions (primary lung adenocarcinoma) (B) demonstrate areas of fluorescence corresponding to areas of carcinoembryonic antigen–related cell adhesion molecule type 5 (CEACAM5) staining that were also congruent with areas of TTF-1 expression, demonstrating CEACAM5-dependent SGM-101 labeling. Adjacent normal lung parenchyma (inset, C) demonstrates a lack of fluorescence and a lack of CEACAM5 staining. H&E indicates hematoxylin-eosin.CEACAM5 Receptor–Targeted Intraoperative Molecular Imaging to Detect Lung Cancer. The video shows the use of carcinoembryonic antigen–related cell adhesion molecule type 5 (CEACAM5) receptor–targeted intraoperative molecular imaging on (A) a CEACAM5-positive tumor, (B) a benign, CEACAM5-negative nodule, (C) a CEACAM5-positive tumor in situ, and (D) a bisected CEACAM5-positive tumor.